[Form 4] ANAPTYSBIO, INC Insider Trading Activity

Rhea-AI Filing Summary

ANAPTYSBIO, Inc. (ANAB) director John A. Orwin received a grant of 1,300 restricted stock units (RSUs) reported on Form 4 with a transaction date of 09/15/2025. Each RSU represents a contingent right to one share of common stock to be settled for no consideration. The filing shows 10,665 shares beneficially owned by Mr. Orwin following the reported transaction. The RSUs are subject to a time-based vesting schedule stated in the filing: one‑third vested on 09/15/2024, one‑third on 09/15/2025 and the final one‑third on 09/15/2026, each tranche conditioned on continued service. The Form 4 was signed by an attorney‑in‑fact on 09/17/2025.

Positive

• Alignment of interests: The RSUs will convert to common stock for no consideration, tying the director's compensation to shareholder value.
• Time‑based vesting: The three‑year vesting schedule supports retention and continued service.

Negative

• None.

Insights

Financial Analyst

TL;DR: A routine director RSU grant that aligns management and shareholder interests; not materially dilutive.

The Form 4 documents a time‑based grant of 1,300 RSUs to a director with settlement for no cash consideration and a three‑year vesting schedule. For a company with publicly traded equity, this size of grant is modest relative to typical board compensation plans and appears intended to retain and align the director with shareholders. The filing shows the director now beneficially owns 10,665 shares after the grant. There are no cash proceeds, new debt, or derivative exercises reported, and no other compensation changes disclosed in this filing.

Corporate Governance Expert

TL;DR: Standard equity compensation disclosure for a director; vesting tied to continued service.

The document is a standard Section 16 disclosure showing grant economics and vesting terms: RSUs settle into common stock for no consideration and vest in three equal tranches over three specified anniversaries. The record identifies the reporting person as a director and the filing was executed by an attorney‑in‑fact. There is no indication of accelerated vesting, related‑party transactions, or changes to committee assignments in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Orwin John A

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		M		1,300	A	$0(1)	10,665	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	09/15/2025		M			1,300	(2)	(2)	Common Stock	1,300	$0	1,300	D

Explanation of Responses:

1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date.

	/s/ Eric Loumeau, Attorney-in-Fact	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did ANAB director John A. Orwin report on Form 4?

The Form 4 reports a grant of 1,300 restricted stock units (RSUs) with a transaction date of 09/15/2025.

How many shares does John A. Orwin beneficially own after the reported transaction?

The filing reports Mr. Orwin beneficially owns 10,665 shares following the transaction.

What are the vesting terms for the RSUs reported on ANAB Form 4?

The RSUs vest in three equal installments: 1/3 on 09/15/2024, 1/3 on 09/15/2025, and 1/3 on 09/15/2026, subject to continued service.

Did the reporting person pay cash for the RSUs?

No. The filing states each RSU represents a contingent right to receive one share upon settlement for no consideration.

Who signed the Form 4 and when was it signed?

The Form 4 was signed by /s/ Eric Loumeau, Attorney‑in‑Fact on 09/17/2025.